All Stocks/Healthcare/PRAX

Praxis Precision Medicines, Inc.

PRAX
HealthcareBiotechnology Website
Price ChartPowered by TradingView
Ask about PRAXAI research agent
Top Institutional HoldersFrom 13F filings
FundShares HeldPosition ValueAction (latest Q)
Point72
Steve Cohen
992K$292.48MNEW
Citadel
Ken Griffin
139K$41.00MNEW
Marshall Wace69K$20.41MNEW
Renaissance Technologies
Jim Simons (founder)
66K$19.52MNEW
D.E. Shaw
David Shaw
47K$13.99MNEW
Hussman Investment Trust
John Hussman
8K$2.48MNEW
About Praxis Precision Medicines, Inc.

Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.

CEO
Mr. Marcio Silva De'Souza M.B.A.
Employees
168
Quick Facts
Exchange
SectorHealthcare
IndustryBiotechnology
Market Cap
Key Dates

Earnings calendar coming soon. Subscribe to get notified when PRAX reports next.

Get earnings alerts →